Maze Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Maze Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$142.90M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$131.12M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.05
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.05

Balance Sheet

	2025-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$189.25M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$397.13M
Everything the company owes — debt, unpaid bills, and other obligations.	$42.16M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$354.97M

Cash Flow Statement

	2025-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$111.94M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$794000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$112.73M

Peer Comparison

	You	Peer avg
P/E	–	12.1
Revenue Growth	–	+16.7%
ROE	-37.3%	9.2%